AlphaYouCLYM: Thomas Stephen Basil discloses a sale
By AlphaYouPublished Form 4
Thomas Stephen Basil
Reporting filer
Thomas Stephen Basil reported Sale in Climb Bio, Inc.: 100000 units of Common Stock, dated 2026-09-15. The full Form 4 contains 1 transaction entry.
- Disclosed
- Sep 17, 2026
Reported details
1 entry| Security | Owner | Date | Code | Action | Quantity | Price | Following holdings | Reporting delay | Filed terms and references |
|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Thomas Stephen Basil | 2026-09-15 | S | Sale | 100000 | 13.6682 | 467,969 | 2 days | Filed terms
|
Common Stock
- Owner
- Thomas Stephen Basil
- Date
- 2026-09-15
- Code
- S
- Action
- Sale
- Quantity
- 100000
- Price
- 13.6682
- Following holdings
- 467,969
- Reporting delay
- 2 days
- Filed terms and references
Filed terms
- security Title: Common Stock
- transaction Date: 2026-09-15
- transaction Form Type: 4
- transaction Code: S
- equity Swap Involved: false
- id: F1
- transaction Shares: 100000
- transaction Price Per Share: 13.6682
- id: F2
- transaction Acquired Disposed Code: D
- shares Owned Following Transaction: 467969
- id: F3
- direct Or Indirect Ownership: D
Purchases, sales, grants and option exercises are different transactions. The reported code identifies the action; it does not establish a motive.
Filing context
- Quantities and prices are shown in the units filed. No trade value is inferred from their product.
- Thomas Stephen Basil: Director.
- The filing reports a Rule 10b5-1 trading plan.
- F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2026.
- F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.3800 to $14.3400, inclusive. The reporting person undertakes to provide the staff of the Securities and Exchange Commission, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
- F3: Includes 413,312 shares of the issuer's common stock, par value $0.0001 per share, distributed by Sera Medicines, LLC to certain of its limited partners, including the reporting person, for no consideration in a pro-rata in-kind distribution.
Original sources
Prepared automatically from public filing data. Report a correction.